Cite
HARVARD Citation
Yang, S. et al. (2021). Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet infectious diseases. 21 (8), pp. 1107-1119. [Online].